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Abstract 
Depression is one of the leading causes of disease-related disability in women, and they are 
nearly twice as likely as men to suffer from an episode of depression.  The difference begins 
in early life and persists through to mid-life, and as such, these reproductive years have been 
labelled by some as a ‘window of vulnerability’.  The prevalence has been reported to be 
particularly high during the menopausal transition, but there is no consensus supporting a 
direct association with reproductive status.  This may be partly due to methodological 
limitations and inconsistencies in the available studies, resulting from a large number of 
confounding factors.  In addition, relationships between sex hormones and the 
neurotransmitters purported to be responsible for depression are complex.  What appears to 
be universally accepted is that treatment, with oestrogen, for low mood in women during 
midlife years may be beneficial, and should be considered. 
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Searching 
All searches were conducted in PUBMED and EMBASE. The following search terms were 
combined using Boolean rules: depression, menopause, midlife, women.  All searches were 
updated June 2016.   
Searching of grey literature or unpublished literature was not undertaken.  Papers published 
in languages other than English were not reviewed.   
The titles and abstracts of records retrieved by the searches were sifted for relevance, with 
potentially significant publications obtained in full text.   
  
Introduction 
Depression is a broad and heterogenous diagnosis, with depressed mood and/or loss of 
pleasure in activities at the core (1).  Severity is judged by the number and severity of 
symptoms, as well as the degree of functional impairment, however, persistent symptoms 
below the threshold criteria (ICD-10 and DSM-IV) can be distressing and disabling.  It is one 
of the leading causes of disease-related disability in women (2), and they are nearly twice as 
likely, compared with men, to suffer from an episode of depression (3-5).  This difference 
begins early in life (adolescence) and persists through the mid-50s (6, 7).  Therefore, it would 
appear that women are more at risk of depression during their reproductive years.   
Biological, social and psychological factors have a significant impact on the course of 
depression and the response to treatment, and in a recent review, Noble (8) noted that several 
biological processes have been thought to be involved in the predisposition of women to 
depression, including genetically determined vulnerability, hormonal fluctuations, and an 
undue sensitivity, to hormones, in brain systems that mediate depressive states.  He also 
included psychosocial events; role-stress, victimization, sex-specific socialization, 
internalization coping style, and disadvantaged social status as contributors to the increased 
vulnerability of women to depression.  Once the first episode has occurred, neither chronicity 
nor acute episode recurrence plays an important part in determining the higher rate of active 
depression among women, compared with men, in the 15-54 year age range, but the reasons 
behind this sex discrepancy are not entirely clear.   
 
 
 
Depression: A definition 
Symptoms of depression can be psychological, physical and/or social.  Psychological 
symptoms  may include feelings of low mood, sadness, hopelessness, low self-esteem, 
feelings of guilt, irritability and intolerance, a lack of motivation or interest, difficulty in 
making decisions, and thoughts of self-harm or suicide.  Physical symptoms include changes 
in sleep pattern, changes in weight and appetite, unexplained aches and pains, and a lack of 
energy or loss of interest in sex.  Social symptoms include reduced productivity at work, 
avoidance of social activities and friends, and difficulty with home and family life. 
The Diagnostic and Statistical Manual of Mental Disorders (DSM) is published by the 
American Psychiatric Association and is the official diagnostic system for mental disorders in 
the United States.  The International Classification of Diseases (ICD), used more widely in 
Europe, is the international standard diagnostic tool for epidemiology, health management 
and clinical purposes.  A survey of Psychiatrists suggests that the former is of more value in 
research whilst the ICD is more frequently used for clinical diagnosis (9).  
DSM describes major depressive disorder (MDD) as two or more major depressive episodes, 
characterised by depressed mood and/or loss of interest or pleasure in life activities for at 
least two weeks and including at least five symptoms (see below) that cause clinically 
significant impairment in social, work, or other important functioning almost every day. 
1. Depressed mood most of the day 
2. Diminished interest or pleasure in all or most activities 
3. Significant unintentional weight loss or gain 
4. Insomnia or sleeping too much 
5. Agitation or psychomotor retardation noticed by others 
6. Fatigue or loss of energy 
7. Feelings of worthlessness or excessive guilt 
8. Feelings of worthlessness or excessive guilt 
9. Diminished ability to think or concentrate, or indecisiveness. 
10. Recurrent thoughts of death 
 
Chronic symptoms of depression not meeting criteria for a major depressive episode may 
represent a dysthymic disorder, which is described as depressed mood for most of the day, for 
more days than not, for at least 2 years, and the presence of two or more symptoms (see 
below) that cause clinically significant impairment in social, work, or other important areas 
of functioning: 
1. Poor appetite or overeating 
2. Insomnia or sleeping too much 
3. Low energy or fatigue 
4. Low self-esteem 
5. Poor concentration or difficulty making decisions 
6. Feelings of hopelessness 
 
The ‘window of vulnerability’ 
Depression in women has long been linked to the reproductive cycle and premenstrual 
syndrome (PMS), with associated mood disturbances, regularly recurs during the luteal phase 
of each menstrual (ovarian) cycle. 
Absence of PMS before puberty, in pregnancy and after the menopause supports the theory 
that cyclical ovarian activity is important.  Other reproductive events include postpartum 
depression and the ‘baby blues’, and this relationship between depression and the 
reproductive years has been described by Soares as a ‘window of vulnerability’ (10); and has 
been supported by epidemiological data.  It is also noted that this window may be influenced 
by changes in metabolism, sexuality, lifestyle, and overall health. 
There may be significant psychosocial factors which may present at the time that a woman 
reaches menopause.  There may be changes in the family structure, children leaving home, 
changes at work, possibly retirement.  There may be additional caregiving responsibilities, 
for parents or in-laws, a well-known risk factor for depression. Although a single factor is 
unlikely to be causative, they may certainly contribute to depression. 
The extent to which the risk of depression can be attributed purely to the menopause is less 
clear, there are supporting data (11), however, there are many methodological limitations and 
inconsistencies in the studies attempting to address this question; including variations in the 
definition of menopause as well as a lack of standardisation of psychiatric symptoms.   
Indeed, some women will report symptoms of depression, but will never develop clinical 
depression (Major Depressive Disorder).  The Harvard Study of Moods and Cycles (12), a 
population-based prospective study of premenopausal women with and without a lifetime 
history of major depression, was designed to address this.  The findings demonstrated a two-
fold increased risk of significant depressive symptoms in those who entered the 
perimenopause, compared with those women who remained premenopausal, after adjustment 
for age at study enrolment and history of negative life events. The increased risk for 
depression was somewhat greater in women with self-reported vasomotor symptoms. 
The Penn Ovarian Ageing Study (13) provides evidence in support of these findings, and 
describes a diagnosis of depressive disorder 2½ times more likely to occur in the menopausal 
transition compared with when the woman was premenopausal (odds ratio, 2.50; 95% 
confidence interval, 1.25-5.02; P=.01).  After adjusting for smoking, BMI, flushes, and other 
socioeconomic factors, within-woman change in menopausal status, increased levels of FSH 
and LH, and increased variability of oestradiol, FSH, and LH around the woman's own mean 
levels were each significantly associated with high Centre for Epidemiological Studies of 
Depression scale (CES-D) scores.  This provides further support for the impact of fluctuating, 
rather than absolute, hormone levels on the risk of depression. 
The Study of Women’s Health Across the Nation (SWAN) over ten years (14) addressed four 
questions; 1) does the menopausal transition or postmenopause render women more 
vulnerable to depression than does the premenopause? 2) does the risk for depression vary by 
race/ethnicity or by differing influences on risk by menopausal status among different ethnic 
groups? 3) if depression is more prevalent during or after the transition, is this due to 
hormonal alterations, psychological, developmental, and/or somatic change associated with 
the transition, midlife (more generally) or genetic vulnerability, and 4) what are the risk 
factors for depression during midlife and what is the impact of menopausal status on 
depression relative to other factors? 
Women were more likely to report a high CES-D score when early perimenopausal, late 
perimenopausal, and postmenopausal relative to when they were premenopausal.  Japanese 
and Hispanic women were more likely to report a high CES-D score compared with 
Caucasians.  Significant predictors for a high CES-D score included vasomotor symptoms 
[OR (95% CI)1.62 (1.43–1.84)] being a current smoker, low social support, very stressful 
events, financial strain, a high BMI [OR (95% CI)1.01 (1.001–1.03)] (every 1 unit increased 
the odds by 1%), and having less than a college education.  High social support was 
protective and reduced the odds by nearly 20% [OR (95% CI)0.81 (0.79–0.83)]. 
Most importantly menopausal status was associated with a two to four times increased 
likelihood of experiencing a major depressive episode, perimenopausal [odds ratio 
(OR)=2.27] or postmenopausal [odds ratio (OR) =3.57], independent of stressful life events, 
hormones or vasomotor symptoms (VMS).  The strongest predictor of major depression is a 
past history of major depression. 
Interestingly, whilst cyclical ovarian activity has long thought to be a key factor in the risk of 
depression, SWAN demonstrated an association with testosterone only.  A recent cross-
sectional Australian study reported an excess of depressive symptoms during menopausal 
transition [direct odds ratio (OR) 1.35, 95% CI = 0.90, 2.01] and early postmenopause [direct 
odds ratio (OR) 1.31, 95% CI = 0.87, 1.98], but this was not significant and as such it was 
concluded that this excess could not be directly attributed to reproductive status (15).  In 
support of SWAN data, a past history of depression was associated with increased odds of 
major depressive symptoms, as were the presence of risky alcohol use, self-reported arthritis, 
chronic pain, postnatal depression, and anxiety.    
 
Anxiety 
Studies on anxiety are sparse, however, women who report a history of depression and 
anxiety may report worse quality of life during the midlife years, independent of vasomotor 
symptoms and sleep disturbance (16).  From SWAN, Bromberger described a surge in 
anxiety during late perimenopause, in those women without a history of anxiety.  VMS were 
strongly associated with the occurrence of anxiety (17) both in women with and without a 
history of anxiety at the start of the follow-up. 
In Soares review (10), 3 randomised controlled trials (RCTs) were identified, and all failed to 
show any beneficial effects of HRT on anxiety symptoms, however it is noted that this may 
be explained, in part, by low anxiety scores on entry to the study.  
 
Sleep disturbance 
Women often complain of difficulties initiating and/or maintaining sleep during the 
menopausal transition.  It is difficult to determine whether this is a primary disorder or 
whether it may be related to underlying vasomotor symptoms, or depression.  It may also be 
related to coexistent medical conditions, or lifestyle.  Obstructive sleep apnoea and restless 
leg syndrome, are also common sleep problems in this age group, and as such can also 
worsen the sleep quality (18).  
Possible interactions between menopause changes and sleep disturbance have been 
investigated, and menopausal transition was associated with the onset of sleep disturbances 
(19).  There have been studies which have shown that it is in fact VMS that are the primary 
predictor of sleep problems in menopausal women (20), however, whilst sleep disturbance 
has been shown to be associated with depression in midlife women when compared with their 
non-depressed contemporaries, and there was worse sleep quality in those with VMS who 
were depressed, compared with those with VMS who were not depressed, there were no more 
nocturnal VMS, or increased number of awakenings in the depressed group (21).  Therefore, 
in this group, the sleep disturbance does not appear to be caused by nocturnal VMS. 
These findings are supported by improvements in sleep quality through the use of a sleep aid 
(zolpidem), with no improvement in flush number during the day, suggesting that women 
were actually sleeping all night with no change in nocturnal VMS. 
 
Sexual Dimorphism 
In a recent review by Panzica (22), it is noted that sexually dimorphic behaviours may be 
suggestive of sex differences in brain neuroanatomy and neurophysiology.  Perhaps this may 
in part explain why women are nearly twice as likely to suffer from an episode of depression, 
compared with men.   
The link between gonads and differences in sexual behaviour was first demonstrated by 
Berthold (a German Physiologist), in 1849, during his experiments with roosters.  He 
observed that it was not only phenotypical characteristics that were dependent on the testes, 
but also behaviours.  Since these early experiments, anatomical differences in the 
hypothalamus, including a sexually dimorphic nucleus (SDN) within the median preoptic 
area (MPOA), with higher volumes and cell numbers in male rats compared with female rats 
(23, 24), and this has subsequently been described in different vertebrate species, including 
humans (25). 
The preoptic area is responsible for reproduction, thermoregulation, and sleep, via a complex 
network of regulatory signals, which include neurotransmitters, neuropeptides and hormones.  
Serotonin (5-HT) is one of these neurotransmitters and may be involved in thermoregulation 
as well as sleep and release of gonadotrophin-releasing hormone (GnRH).  Changes in 5-HT 
receptors and transporters are reported in aging, and animal studies have reported that these 
preoptic neurons are affected during reproductive aging (26).  Further work would be needed 
to determine whether this may play a role in the pathophysiology of depression during 
reproductive aging in humans and whether sexual dimorphism in this area can explain the 
differences seen in men and women. 
Gonadal steroids, oestradiol and progesterone have also been shown to have an effect on 
gamma-aminobutyric acid (GABA), as well as noradrenaline and serotonin, all of which are 
implicated in the development of depression (27).  The expression of the enzyme required for 
GABA synthesis is sexually dimorphic in discrete regions of the hypothalamus, and also in 
amygdala and the hippocampus (28).  GABA also appears to be sensitive to oestradiol during 
the sensitive period of steroid-mediated brain sexual differentiation (29). 
Brain-born oestradiol has been shown to rapidly block GABA release in females, but not in 
males, due to generation of inositol triphosphate and activation of its receptor (IP3R).  The 
complexes of ERα, glutamate receptor and IP3R are present in both sexes, but are regulated 
by oestradiol only in females (30). 
Tyrosine-hydroxylase (TH), the rate-limiting enzyme involved in dopamine synthesis, has 
also been shown to be sexually dimorphic, particularly in the anterior preoptic area, and the 
arcuate nucleus (31, 32).  Recent studies have shown that at least part of these two 
populations of dopaminergic neurons also express kisspeptin (33). 
The kisspeptin/neurokinin B/dynorphin signalling system in the hypothalamus is the key 
proximate stimulus to GnRH secretion: individuals with inactivating mutations in the genes 
encoding kisspeptin or neurokinin B or their receptors do not enter puberty (34).  The 
kisspeptin system is another sexually dimorphic system, with higher numbers of cells and 
fibres in the female than in the male (33).   
Kisspeptin neurones are a key locus of sex steroid feedback in the hypothalamus, and in 
humans, administration of kisspeptin stimulates gonadotrophin secretion in men and women, 
with increases in GnRH/LH pulse frequency (35).  Post-mortem studies have shown 
hypertrophy of neurons in the hypothalamic infundibular nucleus in postmenopausal women 
(36) with increased NKB and kisspeptin gene expression (37). Ovariectomy resulted in 
similar changes in young monkeys (38), and oestrogen suppressed NKB and kisspeptin 
expression (39).  Kisspeptin, Neurokinin B and Dynorphin (KNDy) neurones in the 
hypothalamus are thus obligate regulators of GnRH secretion across species, and are sensitive 
to oestrogen withdrawal.   
Animal studies have also demonstrated some behaviour associations with kisspeptin and its 
receptors, including anxiety and depression (40); as the upstream regulator of GnRH in 
humans, and considering its complex relationship with 5-HT, alterations seen in kisspeptin in 
the postmenopause period may play a role in mood regulation in women during their midlife 
years.  
 
Oestrogen receptor polymorphisms 
Oestrogen receptors are found throughout the brain, and the effects of oestrogen can be 
observed in the hypothalamus, prefrontal cortex, hippocampus, and brainstem.   
In animal models, withdrawal of estrogens has been proposed to play a key role in the onset 
of postpartum anxiety and depression, which typically occur within 4–6 weeks after birth.  
However, circulating estrogen levels, which are drastically reduced during the early 
postpartum period, return to diestrus levels by 3 weeks postpartum, raising the possibility that 
changes in estrogen sensitivity are involved in the postpartum response (41).  
Oestrogen receptors ER-α and ER-β are transcribed from two genes, ESR1 and ESR2, 
respectively, and allelic variation in these two receptors, especially ESR1, has been shown to 
be associated with some health outcomes, i.e. breast cancer (42), high density lipoprotein 
cholesterol (43), and all-cause mortality (44).  There has also been increasing interest in the 
way in which allelic variation in these genes may influence depression, suggesting that ER 
genes might be important in the pathophysiological mechanism of post-menopausal 
depression.   
In humans, ERa receptor polymorphism has been shown to have an association with 
depression in post-menopausal women (45), and in the Nurse’s Health Study (46) women 
with the AA alleles of ESR2 RS4986938 had higher prevalence of lifetime major depression 
than women with other allele frequencies.  However, the date are inconsistent, and 
population-based studies that have evaluated the role of allelic variation in oestrogen 
receptors and depression have been mixed (47). 
 
Serotonin receptor polymorphisms 
5HTT is an integral membrane protein that moves the serotonin neurotransmitter from the 
synaptic cleft to the presynaptic neurons.  A functional serotonin-transporter-linked 
polymorphic region (5-HTTLPR) polymorphism is characterized by the insertion or deletion 
of a 44-bp fragment and, consequently, the creation of a short or a long allele.  A short allele 
has a lower ability to uptake serotonin than a long allele.  A small study examined whether 
the presence of a serotonin transporter polymorphism was associated with the development of 
depressive symptoms in late-reproductive-age women.  There was no association 
demonstrated (48). 
 
Tentative links 
No links have been found between levels of Vitamin B12 and folate and the risk of 
depression in women in the midlife years (49).  Neither do biomarkers of omega-3 appear to 
be related to risk of new depression in postmenopausal women (50), however, women with 
higher serum magnesium and zinc levels had fewer depressive symptoms (51), although this 
was a small study of only 171 women. 
 
Treatment 
There are numerous studies that have demonstrated the beneficial effects of oestrogen on 
mood in midlife women (52-55).  The Revised Global Consensus Statement on Menopausal 
Hormone Therapy (56) states that “MHT (menopausal hormone therapy) may be beneficial in 
improving mood in early postmenopausal women with depressive and/or anxiety symptoms.  
MHT may also be beneficial for perimenopausal women with major depression but 
antidepressant therapy remains first-line treatment in this setting”.  Very recently published 
NICE guidance for Menopause (57) supports the consideration of HRT to alleviate low mood 
that has arisen as a result of the menopause. 
Antidepressants are not routinely used to treat persistent subthreshold depressive symptoms 
or mild depression because the risk–benefit ratio is poor, but an SSRI may be considered in 
those who have not benefited from a low-intensity psychosocial intervention (1). 
Oestrogen increases the synthesis and availability of 5-HT, by decreasing the activity of the 
enzymes involved in 5-HT degradation, monamine oxidase inhibitors A and B (58), and 
increases in tryptophan hydroxylase, the rate-limiting enzyme of 5-HT synthesis (59).  
Oestrogen also regulates 5-HT transporters, used for reuptake to the presyntatic cleft.  
Blocking these receptors to increase available 5-HT is the basis by which antidepressants, 
selective serotonin reuptake inhibitors (SSRI) and serotonin and noradrenaline reuptake 
inhibitors (SNRI) work in the treatment of depression.  There is increased 5-HT in the 
synaptic cleft with oestrogen as a result of down-regulation of 5-HT1A autoreceptors and 
upregulation of 5-HT2A receptors (10).  
Brain concentrations of progesterone and allopregnanolone are altered in animal models of 
anxiety and depression (60), and pharmacological treatment with antidepressants, 
antipsychotics and mood stabilisers restore altered central and peripheral concentrations of 
allopregnanolone (61), suggesting that neuroactive steroids may contribute to the therapeutic 
efficacy of antidepressant medications. 
PET studies of patients with depression have supported the role of serotonin in depression, 
however only a few studies have used PET to study the role of gonadal hormones in 
depression in humans.  A recent study demonstrated a decrease in 5-HTT binding potential 
after both oestrogen alone and oestrogen + testosterone treatment compared to baseline, 
further supporting the role of gonadal hormones in serotonin regulated mood disorders (62). 
The ancillary Cognitive and Affective Study (KEEPS-Cog) of the Kronos Early Estrogen 
Prevention Study (KEEPS), a randomised, double-blinded, placebo controlled clinical trial, in 
9 US academic centres, demonstrated beneficial mood effects in recently postmenopausal 
women with 4 years of CEE, but not with 4 years of E2 (63). 
Isoflavones and red clover may improve anxiety for women with menopausal symptoms, but 
caution should be exercised as there is a lack of consistency between the constituents of 
herbal preparations, isoflavones and phytoestrogens (57). 
Psychotherapy, including cognitive behavioral therapy, interpersonal therapy, and 
psychodynamic psychotherapy may be beneficial for some women, alone or in conjunction 
with prescribed antidepressants (64, 65). 
Obesity and a sedentary lifestyle are associated with depressive symptoms and anxiety in 
women during midlife years (66)  The Canadian Network for Mood and Anxiety Treatments 
(CANMAT) produced clinical guidelines for the management of adults with MDD, and 
recommended exercise, light therapy, St. John's wort, omega-3 fatty acids, SAM-e, and yoga 
as first- or second-line treatments for mild to moderate MDD.  Adjunctive exercise and 
adjunctive St. John's wort are second-line recommendations for moderate to severe MDD 
(67). 
 
Is depression a risk factor for other morbidities? 
Depression is associated with multiple medical conditions and symptoms, including mortality 
from cardiovascular disease (CVD) (68, 69), and diabetes (70), and can be both a risk factor 
for and a consequence of illness (14). 
However, depression can be associated with lifestyle factors that can cause disease, for 
example, smoking, excess alcohol intake, obesity and a sedentary lifestyle.  Therefore 
interpretation of the data can be challenging.  The Million Women Study, a prospective study 
of UK women recruited between 1996 and 2001, demonstrated that poor health can cause 
unhappiness in middle-aged women, but after adjustment for potential confounders, 
happiness and other measures of wellbeing did not appear to have any effect on mortality 
(71).  There was some excess mortality when adjusting only for age, but when adjusted for 
other measures, there was no association for all-cause mortality, ischaemic heart disease, or 
cancer.  Interestingly, the authors suggest that whilst adjustment has been made for 
confounders that may affect health and mortality adversely, e.g smoking, these should 
perhaps be considered mediators of the unhappiness-mortality association. 
 
Conclusion 
Women in the midlife are at an increased risk of low mood and depression; however it is still 
not clear whether this is directly attributable to reproductive status.  Whilst it is likely that 
this is related to the changing hormonal milieu, the complex relationships that exist between 
gonadal steroids and neurotransmitters, and their receptors, mean that this pathophysiology is 
still poorly understood.  A past history of depression seems to be the most important risk 
factor, but there are a number of confounding factors, not limited to, but including comorbid 
medical conditions, education, and hazardous lifestyle choices.  What is clear is that there 
may be some benefit in treating low mood with oestrogen replacement, which is likely to 
improve vasomotor symptoms, if present, and may, as a consequence, improve associated 
symptoms of anxiety.  CBT may be beneficial for some women, but caution must be 
exercised with herbal preparations, isoflavones and phytoestrogens due to inconsistencies in 
preparations.  Above all, it is imperative that we consider all possible causes of low mood, as 
well as associations of depression with other co-morbidities, and aim to optimise midlife 
health.  
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